TLDR Nvidia is partnering with healthcare AI startup Abridge to build a clinical AI model tailored for doctor-patient conversations. The model will be built onTLDR Nvidia is partnering with healthcare AI startup Abridge to build a clinical AI model tailored for doctor-patient conversations. The model will be built on

Nvidia (NVDA) Stock: The Chip Giant Moves Deeper Into Healthcare With Abridge Partnership

2026/06/11 21:48
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

TLDR

  • Nvidia is partnering with healthcare AI startup Abridge to build a clinical AI model tailored for doctor-patient conversations.
  • The model will be built on Nvidia’s open Nemotron model family and run exclusively within Abridge’s platform.
  • The model will support clinical tasks like documentation and clinical decision support.
  • Abridge, valued at $5.3 billion, uses AI to transcribe and summarize doctor-patient conversations.
  • The model is expected to be ready later this year; Nvidia is an existing investor in Abridge.

Nvidia (NVDA) is teaming up with healthcare AI startup Abridge to develop an artificial intelligence model built specifically for clinical conversations. The partnership was reported by the Wall Street Journal on June 11.


NVDA Stock Card
NVIDIA Corporation, NVDA

NVDA stock was trading around $137 at the time of the report.

The new model will be trained on Nvidia’s family of open models, called Nemotron. It will be used exclusively inside Abridge’s platform to improve clinical documentation and decision support.

Abridge is a Pittsburgh-based startup that captures and transcribes conversations between doctors and patients. It also generates automated clinical notes, patient visit summaries, and validates billing codes.

Why Open Models?

Abridge’s director of applied science Davis Liang said cost was a key factor in choosing Nvidia’s open models. Smaller, purpose-built open models are cheaper to run than proprietary ones, and can be deployed on Abridge’s own hardware.

Abridge will use its de-identified clinical data to fine-tune the Nemotron models. CEO Shiv Rao said generic models aren’t enough on their own — clinical intelligence still needs to be trained and tested against real-world conditions.

The model is expected to be ready to deploy later this year. It will be one of several models powering Abridge’s platform.

Nvidia’s Push Into Healthcare

Kimberly Powell, Nvidia’s vice president of healthcare, said the Abridge work is one example of how its open models can be applied across healthcare and life sciences — including drug discovery, medical devices, and digital health.

Nvidia is already an investor in Abridge, which raised $300 million in funding last year at a $5.3 billion valuation. Founded in 2018, the company has grown its ambient-listening tech across major health systems.

Dr. Joon Lee, CEO of Emory Healthcare in Georgia, said he has deployed Abridge’s platform to more than 3,000 physicians across the system. He expects the new Nvidia-backed model to accelerate the development of the tech.

The partnership comes as other tech companies make similar moves. Last week, Microsoft announced a collaboration with Mayo Clinic to build a healthcare AI model using Mayo’s clinical data. OpenAI and Anthropic also have healthcare offerings.

Abridge held an event in New York City on Thursday to announce further enhancements to its platform.

The post Nvidia (NVDA) Stock: The Chip Giant Moves Deeper Into Healthcare With Abridge Partnership appeared first on CoinCentral.

Market Opportunity
Gensyn Logo
Gensyn Price(AI)
$0.02762
$0.02762$0.02762
-1.10%
USD
Gensyn (AI) Live Price Chart

Predict & Trade to Win Rewards

Predict & Trade to Win RewardsPredict & Trade to Win Rewards

Guaranteed rewards with $500,000 prize pool

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

RealStocks Now Live

RealStocks Now LiveRealStocks Now Live

Trade real U.S. stock via regulated brokerage